Acusphere Azione

Acusphere Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di Acusphere (ACUS) al 27 lug 2026 è 27,73 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 80,57 % — una variazione del -65,58% (inferiore).

Conversione FCF

27,73 %

YoY

-65,58%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Acusphere ammonta a 2026 27,73 % . Tasso di Conversione FCF (FCF/EBITDA) di Acusphere ammontava a 2025 80,57 % . Diminuisce del -65,58% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Acusphere Analisi delle Azioni

Cosa fa Acusphere? Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees. The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body. Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of ​​the company is the development of therapies for patients with lung diseases such as COPD or asthma. The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development. Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle. Another important business area of ​​Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects. In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare. Acusphere è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Acusphere azioni

Tasso di Conversione FCF (FCF/EBITDA) di Acusphere è 27,73 % nel 2026.

Access this data via the Eulerpool API

Flussi di cassa — Acusphere

Tutte le Metriche Finanziarie — Acusphere